Celldex Therapeutics reported 0 in Interest Expense on Debt for its fiscal quarter ending in December of 2024.


Interest Expense On Debt Change Date
AbbVie USD 700M 90M Mar/2025
Amgen USD 694M 29M Jun/2025
Bristol-Myers Squibb USD 485M 9M Jun/2025
Celldex Therapeutics 0 0 Dec/2024
Glaxosmithkline 184M 5.95M Jun/2025
Pfizer USD 654M 0 Jun/2025
Roche Holding CHF 311.5M 1000K Dec/2024